JUNS

Jupiter is a pre-revenue, clinical-stage pharma whose entire value rests on JOTROL, an enhanced-resveratrol formulation heading into a Phase IIa Parkinson's trial (IND cleared Nov 2025, dosing expected Q2 2026, read-out ~12 months later). The numbers describe a company running on fumes: FY2025 revenue of just $21.8K against a net loss of $8.64M (widening 254% YoY) and operating cash burn of $5.41M. Stockholders' equity is negative (-$1.83M), current liabilities ($7.40M) exceed all current assets ($4.82M), and total liabilities jumped 264% YoY. Accumulated deficit stands at -$34.7M. The 371x price-to-sales ratio is meaningless — there is essentially no business to value, only a research program.

The filing removes any ambiguity: management and the auditor both flag substantial doubt about the company's ability to continue as a going concern for FY2025 and FY2024. The company states it will require substantial additional capital and warns that raising it 'may cause substantial dilution.' The financing structure is itself a red flag — convertible promissory notes plus a Standby Equity Purchase Agreement (SEPA) that management admits it may be unable to draw on because of low trading volume, with an uncertain number of shares to be issued. Shares already grew 9.6% in the year; a $0.22 stock funding an $8M shell through convertibles and an equity line points to persistent, open-ended dilution for existing holders.